1. QiShenYiQi pill activates autophagy to attenuate reactive myocardial fibrosis via the PI3K/AKT/mTOR pathway.
- Author
-
Lv S, Yuan P, Lu C, Dong J, Li M, Qu F, Zhu Y, and Zhang J
- Subjects
- Animals, Beclin-1 metabolism, Disease Models, Animal, Drug Evaluation, Preclinical, Drugs, Chinese Herbal pharmacology, Fibrosis, Heart Diseases metabolism, Male, Microtubule-Associated Proteins metabolism, Myocardium metabolism, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, Random Allocation, Rats, Wistar, TOR Serine-Threonine Kinases metabolism, Rats, Autophagy drug effects, Drugs, Chinese Herbal therapeutic use, Heart drug effects, Heart Diseases drug therapy, Myocardium pathology
- Abstract
QiShenYiQi pill (QSYQ), a traditional Chinese medicine, is used to treat cardiovascular diseases. However, the dose-effect relationship of its intervention in the reactive myocardial fibrosis is elusive. In this work, rat models of reactive myocardial fibrosis induced by partial abdominal aortic coarctation were constructed and randomly classified into the model group, 3-methyladenine group, rapamycin group, QSYQ low-dose group, QSYQ medium-dose group, QSYQ high-dose group, and sham-operated rats (control group). We revealed that QSYQ lowered the heart mass index (HMI), left ventricular mass index (LVMI), and myocardial collagen volume fraction (CVF) levels in a dose-dependent mechanism. Additionally, QSYQ increased the number of autophagosomes, and the expression of myocardial Beclin-1 and LC3B. In contrast, it reduced the expression of myocardial p62 and decreased the ratios of myocardial p-PI3K/PI3K, p-Akt/Akt, and p-mTOR/mTOR. In conclusion, our results have revealed that QSYQ impacts anti-reactive myocardial fibrosis in a dose-dependent mechanism which is mediated by the activation of myocardial autophagy via the PI3K/AKT/mTOR pathway.
- Published
- 2021
- Full Text
- View/download PDF